Cord Blood Amer Inc. (WKN: A0EAGC / CBAI) / OTCBB

OTCPicks.com: OTCPicks.com Stocks to Watch for Friday, January 30th

PSTI, CBAI, ANPI, ISSC

http://www.quote.com/news/story.action?id=MTO030u6587&pg=5

Shareholder-Letter: http://www.cordblood-america.com/11-13-2008-shareholder-letter.pdf

Cord Blood America, Inc. (OTCBB:CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said that it intends a rapid expansion of its health insurance partnership program to new geographies in 2009. This announcement from Cord Blood America comes on the heels of last week's announcement that the Food and Drug Administration and the U.S. government will allow the world's first test in people of a therapy derived from human embryonic stem cells. For more information, see the social media news room at www.intelligendo.com.

Founder and CEO Matthew Schissler, in reviewing the domestic stem cell industry, predicts that 2009 will be an excellent, milestone year for stem cell storage companies, including CBAI. "Now is the right time. We have focused our business on three primary locations for several years, developing deep relationships with health insurance providers to become their recommended source for storage of umbilical cord blood stem cells."

Mr. Schissler says Cord Blood America's stem cell storage subsidiary, CorCell, will attempt to enter into contracts with two or three more geographic health insurance providers, which would double the company's current health insurance provider base.

"With a national health insurance plan and stem cell agenda as two of the primary topics from the new administration, we see a marriage of the insurance companies possibly paying for stem cell storage on the horizon, even if it is on a limited basis for high risk families. By developing the insurance sales channel, we feel we are positioning ourselves for long term success in becoming a globally dominant stem cell storage company."

Mr. Schissler went on to say that the growth will have limited cost because all infrastructure needed has been put into place over the course of many years.

CBAI has a history of being able to finance its growth, with the most recent funding of $4 million transacting in July of 2008. "With a very low cash burn, we feel we're well financed for the next few years," Schissler commented. "We'll use this time to get cash flow positive and reduce debt while growing both organically and through accretive acquisitions."

The company also is reporting tremendous success in engaging its clients, prospective clients, shareholders and prospective investors via social media with the help and intuition of NetGenPR (www.netgenpr.com). Cord Blood America is currently on Twitter, Facebook and Intelligendo, and soon to be available on FriendFeed. Cord Blood America's address on Twitter is www.twitter.com/cbai. "The conversation has begun. Groups from all over are discussing the impact of stem cells on every day life. We're glad we can lead and moderate this information, while trying to be a stem cell company of the people."

As previously reported, from 2003 to 2007, CBAI focused on growth. In 2008, the Company changed its tactics attempting to de-lever the company while becoming purely a stem cell storage company, and in the process de-emphasizing its non-core family advertising business.

As such, Cord Blood America has reported through first nine months:

* Gross profits for the first nine months have increased to $1.8 million, a 54 percent margin, compared to a 42 percent margin in 2007.

* SGA is down nearly $900,000, a 23 percent savings.

* Loss from operations is down nearly 20 percent.

* Loss per share is down 60 percent, from 0.05 to 0.02.

"We believe 2009 to be a turning point year for CBAI. We're excited to get going," Mr. Schissler concluded.

ANGIOTECH PHARMACEUTICALS INCORPORATED (NASDAQ:ANPI) "Up 18.06% on Thursday"

http://www.quote.com/news/story.action?id=MTO030u6587&pg=4

ANGIOTECH PHARMACEUTICALS INCORPORATED (NASDAQ:ANPI) "Up 18.06% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/ANPI.php

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.

ANPI News:

January 29 - Angiotech's Corporate Partner Boston Scientific Announces Japanese Approval for TAXUS Liberte Drug-Eluting Stent System

Angiotech Pharmaceuticals, Inc. (Nasdaq:ANPI) (TSX: ANP), a global specialty pharmaceutical and medical device company, announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS Liberte paclitaxel-eluting coronary stent system. Boston Scientific plans to launch the product in Japan once reimbursement approval is granted. The TAXUS Liberte was approved by the FDA in October 2008 and was launched in Europe and several other international markets in 2005.

"The TAXUS Liberte stent is the latest advance in drug-eluting stent technology for Japan," said Donald Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "Its safety and efficacy have been well demonstrated in multiple clinical studies and years of clinical use."

"We are pleased to see the approval of TAXUS Liberte in Japan as it demonstrates our partner's commitment to expanding its international acceptance," said Dr. William Hunter, President and CEO of Angiotech. "Japanese patients and their families struggling with coronary artery disease should soon be able to benefit from this proven technology."

TAXUS Liberte is the only second-generation drug-eluting stent approved for use in Japan. The TAXUS Liberte stent will replace the TAXUS Express(2)(TM) stent, marketed in Japan since May 2007. Significant design improvements over the first-generation stent include thinner struts and a more uniform stent geometry.

... früher von dem anstehenden Boom der Stammzellen-Forschung, da hier die Kundschaft bereits für ein Produkt bezahlt! Ich denke bei Werten wie Advanced Cell Tech usw. werden noch viel Forschungsgelder benötigt, dieser Bereich steckt ja immer noch in den Kinderschuhen. Cord Blood America gehört zwar auch zu den forschenden Unternehmen, aber als Storage-Einrichtung wird unmittelbar Umsatz generiert: Hier also für die Aufbewahrung des Nabelschnurrblutes eines neugeborenenen Kindes, um das Familienmitglied in der Zukunft durch die Stammzellenforschung vor Krankheiten schützen zu können.

CBAI verdient an jedem Kunden im ersten Jahr 1925$.
150$ für die Registrierung
150$ für den Kurier Transport
1500$ für die Entnahme
125$ jährlich für die Speicherung

CBAI yearly revenue derzeit: $5,811,000

... am Freitag war das Volumen über 200 Mio, einer der meistgehandelten OTC-Werte an dem Tag.

Gruß, TexX

... wird kräftig gerührt. Alles, was mit Stammzellen zu tun hat, ist derzeit in Bewegung, nicht zuletzt, weil die neue US-Regierung neue Forschungsgelder bereitstellt.

Gruß, TexX

Ganz Amerika diskutiert derzeit über Stammzellen. Kommende Ausgabe (Februar 09) des TIME Magazin:

Authorized is $950M
Can't provide outstanding until auditors check.

All the Best,

Matthew L. Schissler
Chairman & CEO

-----Original Message-----
From: Ax xxx [mailto:xxx@xxx.de]
Sent: Friday, January 30, 2009 12:28 AM
To: pknopick@eandecommunications.com
Subject: CORD BLOOD AMERICA (CBAI) - currently AS / OS ??

Dear Mr. Knopick

can you communicate momentary number AS and OS of CBAI to me?

Regards
Ax xxx

**************************************************

http://investorshub.advfn.com/boards/board.aspx?board_id=3650
Share Structure:
AS: 950M

OS: 309,474,243 Nov 10m 2008

Cord Blood America, Inc. CBAI.OB

Corporate Address:
9000 W. Sunset Boulevard
Suite 400
West Hollywood, CA 90069 USA

Company Contact:
P:(310) 432-4090
F:(310) 432-4098
investors@cordblood-america.com

Investor relations:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com

Transfer Agent
Interwest Transfer Company, Inc.
1981 East 4800 South
Suite 100
Salt Lake City, UT 84117
Phone: (801) - 272-9294
Fax: (801) - 277-3147


Company Officers:
Matthew Schissler - Chairman & CEO - mls@cordpartners.com
Joseph R. Vicente - Director - jvicente@cordpartners.com
Sandra D. Smith - CFO

http://www.emergingcompany.com/program.htm

... eine der großen amerikanischen Krankenversicherungen als Partner von CorCell:

www.msbcbs.com/corcell/members.html

www.corcell.com/healthcare_partners/healthcare_partners.html

"National Labor Office of the Blue Cross Blue Shield Association
... The National Labor Office of the Blue Cross Blue Shield Association maintains a strategic alliance with CorCell to market cord blood services to organized labor and the Blue Cross and Blue Shield health insurance Plans servicing labor throughout the United States. CorCell is dedicated to bringing education and cord blood preservation services to families affiliated with unions across the country..."

Gruß, TexX

http://www.sec.gov/Archives/edgar/data/1289496/...8002118/cord101.htm

http://www.sec.gov/cgi-bin/...e=&SIC=&owner=include&action=getcompany

**************************************************

aktuell letzter Quartalsbericht (Quartal bis 30.09.2008):
http://www.sec.gov/Archives/edgar/data/1289496/...8001912/cbai10q.htm

"With a national health insurance plan and stem cell agenda as two of the primary topics from the new administration, we see a marriage of the insurance companies possibly paying for stem cell storage on the horizon, even if it is on a limited basis for high risk families. By developing the insurance sales channel, we feel we are positioning ourselves for long term success in becoming a globally dominant stem cell storage company."

Mr. Schissler went on to say that the growth will have limited cost because all infrastructure needed has been put into place over the course of many years.

CBAI has a history of being able to finance its growth, with the most recent funding of $4 million transacting in July of 2008. "With a very low cash burn, we feel we're well financed for the next few years," Schissler commented. "We'll use this time to get cash flow positive and reduce debt while growing both organically and through accretive acquisitions."

The company also is reporting tremendous success in engaging its clients, prospective clients, shareholders and prospective investors via social media with the help and intuition of NetGenPR (http://www.netgenpr.com). Cord Blood America is currently on Twitter, Facebook and Intelligendo, and soon to be available on FriendFeed. Cord Blood America's address on Twitter is http://www.twitter.com/cbai. "The conversation has begun. Groups from all over are discussing the impact of stem cells on every day life. We're glad we can lead and moderate this information, while trying to be a stem cell company of the people."

As previously reported, from 2003 to 2007, CBAI focused on growth. In 2008, the Company changed its tactics attempting to de-lever the company while becoming purely a stem cell storage company, and in the process de-emphasizing its non-core family advertising business.

As such, Cord Blood America has reported through first nine months:

-- Gross profits for the first nine months have increased to $1.8 million, a 54 percent margin, compared to a 42 percent margin in 2007.
-- SGA is down nearly $900,000, a 23 percent savings.
-- Loss from operations is down nearly 20 percent.
-- Loss per share is down 60 percent, from 0.05 to 0.02.

"We believe 2009 to be a turning point year for CBAI. We're excited to get going," Mr. Schissler concluded.

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/. To see our social media news room go to http://www.intelligendo.com

http://www.intelligendo.com

http://topics.nytimes.com/top/news/business/...america-inc/index.html

Cord Blood America Inc.
CBAI: OTC Bulletin Board Market; Healthcare/Healthcare Facilities

New York Times
Sunday, February 1, 2009

Company Information
Cord Blood America, Inc. (CBAI) is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for use in stem cell therapy. It is a holding company whose subsidiaries include Cord Partners, Inc. (Cord), CorCell Co. Inc., CorCell Ltd., CBA Professional Services, Inc., doing business as BodyCells, Inc. (BodyCells), CBA Properties, Inc. (Properties), and Career Channel Inc, doing business as Rainmakers International (Rain). On February 28, 2007, the Company acquired CorCell, Inc. On August 1, 2007, it entered into an agreement with Progenitor Cell Therapy, LLC (PCT) for testing, processing and storage of cord blood samples. As a result of the agreement with PCT, the Company terminated its agreement with Bergen Community Regional Blood Center. On August 20, 2007, CBAI acquired specific assets from CureSource, Inc.
Cord Blood America Inc.
501 Santa Monica Blvd Suite 700 Santa Monica CA 90401
Phone: +1 (310) 432-4090

... laut der Investor Presentation 1st. Quarter 2009. Das klingt bei den vergangenen Zahlen glaubwürdig.

@0815ax: danke für den link

Interessant auch zu erfahren, wie man sich die Entwicklung des Kundenstammes bis 2013 vorstellt, denn daran kann man unter anderem erkennen, das der CEO keineswegs an Größenwahn leidet und den Investoren hier was aufschwätzen will. Ich denke eher, das die Schätzungen sogar noch sehr konservativ gehalten sind, denn es kann niemand absehen, was in dieser Branche losbrechen wird...

Gruß, TexX

In den USA im Bundesstaat Georgia ist es bereits ein erlassenes Gesetz: Ab July 2009 müssen alle werdenden Mütter durch Ihren Arzt über die Möglichkeit der Speicherung der Blutzellen aufgeklärt werden!

www.savingthecure.com

www.legis.ga.gov/legis/2007_08/sum/sb148.htm

...The bill provides that, after July 1, 2009, every expectant Georgia mother will be given information by her doctor on the full range of options with regard to postnatal tissue and fluid, including private storage and public donation. Every Georgia mother will be given the opportunity to “save the cure.”...

Gruß, TexX

http://www.cordblood-america.com/...mpany_profile_cordblood_COPY1.pdf

http://finance.yahoo.com/q/h?s=CBAI.OB
http://www.finanznachrichten.de/...hten-aktien/cord-blood-america.asp
http://www.integratir.com/newsrelease.asp?ticker=cbai&title=null

http://www.stemcellresearchnews.com/Headlines_Page.htm

...aktuelle News/Berichte etc.

In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors

Thu Feb 5, 8:01 AM

SANTA MONICA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI.OB), the umbilical cord blood stem cell preservation company (www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, explained that the Company is very close to becoming cash flow positive.

The complete interview is available at www.stoxrox.com/cbai-feb-b.mp3 . "2009 is a tipping point year for Cord Blood America. We will continue our organic growth strategy, adding new health insurance partners and possible new acquisitions, while continuing to reduce debt," Mr. Schissler said.

Cord Blood America's CEO said he was encouraged that more Federal spending on stem cell research under President Obama could lead to more stem cell therapies which, in turn, will lead to more families storing stem cells. "The stem cell agenda is front and center with the new Administration," Mr. Schissler said.

Cord Blood America's CEO also referenced the cover story of the new Time magazine, which cited breakthroughs using stem cells to treat Parkinson's, heart disease and diabetes. "Investors should understand, in storing umbilical cord blood stem cells, we have a significant biological annuity with low bad debt ratio, strong gross profits, and a low cost structure in place that will allow us to take full advantage of the expected increase in the storage of stem cells," the Company's founder said.

About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI.OB) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI.OB), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.



Gruß, TexX

Glaube, die News zeigen Wirkung...

Gruß, TexX

Angiotech's corporate partner, Boston Scientific, submits final modules to FDA for approval of second-generation small vessel and long lesion stents

http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7204017

washingtontimes.com/news/2009/feb/06/...ntees-aiding-stem-cell

The Washington Times - Feb 05 8:33 PM

WILLIAMSBURG| President Obama on Thursday gave lawmakers his "guarantee" he will sign an executive order overturning President Bush's embryonic stem cell research policy.

Meeting with House Democrats holding a retreat here, Mr. Obama answered a question from Rep. James R. Langevin, a Rhode Island Democrat who is a paraplegic, by saying he will sign the order, according to three sources who were in the closed-door part of the meeting.

"I guarantee you that we will sign an executive order for stem cells," Mr. Obama said, according to the sources who requested anonymity because they were not authorized to talk about the closed-door portion of the meeting.

Mr. Obama said the executive order would be coordinated with Congress on timing, and said it was important that Congress also pass a law codifying his order so that a future president couldn't simply reverse the policy back.

...

Gruß, TexX

... vom 7.2.2009

www.cnn.com/2009/POLITICS/02/07/stimulus.cuts/index.html

Gruß, TexX

... danke für den Hinweis!

Da Obama ja nun seine Garantie für die Stammzellenforschung gegeben hat und der US-Senat einige Streichungen vorgenommen hat, würde mich interessieren, um welche Höhe es bei den Forschungsgeldern geht und in welches Ressort das fällt. Eventuell National Institutes of Health grants? Jemand eine Info dazu?

Gruß, TexX

Cord Blood America's CEO also referenced the cover story of the new Time magazine, which cited breakthroughs using stem cells to treat Parkinson's, heart disease and diabetes. "Investors should understand, in storing umbilical cord blood stem cells, we have a significant biological annuity with low bad debt ratio, strong gross profits, and a low cost structure in place that will allow us to take full advantage of the expected increase in the storage of stem cells," the Company's founder said.

About Cord Blood America

Cord Blood America (OTC:CBAI) (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC:CBAI) (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT: Paul Knopick E & E Communications 949/707-5365

DATASOURCE: Cord Blood America, Inc.

CONTACT: Paul Knopick, E & E Communications, +1-949-707-5365,

, for Cord Blood America, Inc.

Web Site: http://www.cordblood-america.com/

   * Lower costs for businesses by covering a portion of the catastrophic health costs they pay in return for lower premiums for employees.
   * Prevent insurers from overcharging doctors for their malpractice insurance and invest in proven strategies to reduce preventable medical errors.
   * Make employer contributions more fair by requiring large employers that do not offer coverage or make a meaningful contribution to the cost of quality health coverage for their employees to contribute a percentage of payroll toward the costs of their employees' health care.
   * Establish a National Health Insurance Exchange with a range of private insurance options as well as a new public plan based on benefits available to members of Congress that will allow individuals and small businesses to buy affordable health coverage.
   * Ensure everyone who needs it will receive a tax credit for their premiums.

Reduce Costs and Save a Typical American Family up to $2,500 as reforms phase in:

   * Lower drug costs by allowing the importation of safe medicines from other developed countries, increasing the use of generic drugs in public programs, and taking on drug companies that block cheaper generic medicines from the market.
   * Require hospitals to collect and report health care cost and quality data.
   * Reduce the costs of catastrophic illnesses for employers and their employees.
   * Reform the insurance market to increase competition by taking on anticompetitive activity that drives up prices without improving quality of care.

The Obama-Biden plan will promote public health. It will require coverage of preventive services, including cancer screenings, and increase state and local preparedness for terrorist attacks and natural disasters.

A Commitment to Fiscal Responsibility: Barack Obama will pay for his $50 - $65 billion health care reform effort by rolling back the Bush tax cuts for Americans earning more than $250,000 per year and retaining the estate tax at its 2009 level.

http://www.marketwire.com/press-release/...od-America-Inc-947152.html

Feb 09, 2009 09:35 ET
Cord Blood America Now Part of New ETF Innovators Stem Cell Index

SANTA MONICA, CA--(Marketwire - February 9, 2009) - Cord Blood America, Inc. (OTCBB: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that the Company is now listed on the ETF Innovators Emerging Stem Cell Index of U.S.-listed stocks. For more information, see the social media news room at http://www.intelligendo.com.

ETF Innovators, known for creating new global equity indexes with a focus in the healthcare industry, will track the total market value and stock price changes as an indicator of investor and trader sentiment toward the stem cell and regenerative medicine space.

"We are pleased by this recognition. Two thousand and nine has been, so far, both very interesting and positive for stem cell companies, and we're pleased to see this impressive index following our sector," said Matthew Schissler, Founder and CEO of Cord Blood America.

About Cord Blood America

Cord Blood America (OTCBB: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTCBB: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

09.02.2009 09:07

Gekürztes US-Konjunkturpaket dürfte vor Genehmigung stehen

Washington (BoerseGo.de) - Im US-Senat erzielten am Wochenende Demokraten und Republikaner eine Einigung zum geplanten Konjunkturprogramm der Regierung. Das ausgehandelte Paket umfasst ein Volumen von rund 780 Milliarden Dollar. Damit wurde wegen dem Widerstand der Republikaner der von der Regierung ursprünglich vorgelegte Entwurf um über 150 Milliarden Dollar gekürzt. Das Weiße Haus hat den Kompromiss begrüßt. Zuvor warnte Präsident Barack Obama vor katastrophalen Folgen für die Wirtschaft, falls das Paket zu keiner Verabschiedung gelangt. Der Senat will kommenden Dienstag über den Entwurf abstimmen.


Gruß TexX

Das Time-Magazin mit dem Stem Cell Artikel "How the Coming Revolution in Stem Cells Could Save Your Life" sollte am 9. Februar, also heute in den USA erscheinen.

Das News-Magazin ist laut Wikipedia mit einer Gesamtauflage von rund 5,2 Mio. Exemplaren Marktfüher in den USA.

Gruß, TexX

Filing vom 10.02.2009

http://pinksheets.com/edgar/GetFilingHtml?FilingID=6392580

sowie "OTC Select Announces Morning Daily Stock Watch"

http://www.worldstockwire.com/viewpressrelease/prID/739/

The mutation is known as CCR5 delta32 and is found in 1 percent to 3 percent of white populations of European descent.

HIV uses the CCR5 as a co-receptor (in addition to CD4 receptors) to latch on to and ultimately destroy immune system cells. Since the virus can't gain a foothold on cells that lack CCR5, people who have the mutation have natural protection. (There are other, less common HIV strains that use different co-receptors.)

People who inherit one copy of CCR5 delta32 take longer to get sick or develop AIDS if infected with HIV. People with two copies (one from each parent) may not become infected at all. The stem cell donor had two copies.

While promising, the treatment is unlikely to help the vast majority of people infected with HIV, said Dr. Jay Levy, a professor at the University of California San Francisco, who wrote an editorial accompanying the study. A stem cell transplant is too extreme and too dangerous to be used as a routine treatment, he said.

"About a third of the people die [during such transplants], so it's just too much of a risk," Levy said. To perform a stem cell transplant, doctors intentionally destroy a patient's immune system, leaving the patient vulnerable to infection, and then reintroduce a donor's stem cells (which are from either bone marrow or blood) in an effort to establish a new, healthy immune system.

Levy also said it's unlikely that the transplant truly cured the patient in this study. HIV can infect many other types of cells and may be hiding out in the patient's body to resurface at a later time, he said.

"This type of virus can infect macrophages (another type of white blood cell that expresses CCR5) and other cells, like the brain cells, and it could live a lifetime. But if it can't spread, you never see it-- but it's there and it could do some damage," he said. "It's not the kind of approach that you could say, 'I've cured you.' I've eliminated the virus from your body." Health.com: 10 questions to ask a new partner before having sex

Before undergoing the transplant, the patient was also found to be infected with low levels of a type of HIV known as X4, which does not use the CCR5 receptor to infect cells. So it would seem that this virus would still be able to grow and damage immune cells in his body. However, following the transplant, signs of leukemia and HIV were absent.

"There is no really conclusive explanation why we didn't observe any rebound of HIV," Hutter said. "This finding is very surprising."

Hutter noted that one year ago, the patient had a relapse of leukemia and a second transplant from the same donor. The patient experienced complications from the procedure, including temporary liver problems and kidney failure, but they were not unusual and may occur in HIV-negative patients, he said.

Researchers including Hutter agree that the technique should not be used to treat HIV alone. "Some people may say, 'I want to do it,'" said Levy. A more logical -- and potentially safer -- approach would be to develop some type of CCR5-disabling gene therapy or treatment that could be directly injected into the body, said Levy.

Less invasive options to alter CCR5 could be on the horizon within the next five years, said Levy. "It's definitely the wave of the future," he said. "As we continue to follow this one patient, we will learn a lot."

One drug that's currently on the market that blocks CCR5 is called maraviroc (Selzentry). It was first approved in 2007 and is used in combination with other antiretroviral drugs. Health.com: Who's most at risk for STDs?

In 2007, an estimated 2 million people died from AIDS, and 2.7 million people contracted HIV. More than 15 million women are infected worldwide. HIV/AIDS can be transmitted through sexual intercourse, sharing needles, pregnancy, breast-feeding, and/or blood transfusions with an infected person. Health.com:What should I do if the condom breaks?

"For HIV patients, this report is an important flicker of hope that antiretroviral therapy like HAART [highly active antiretroviral therapy] is not the endpoint of medical research," Hutter said.


Copyright Health Magazine 2009

**************************************************

http://content.nejm.org/cgi/content/abstract/360/7/692

Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Gero Hütter, M.D., Daniel Nowak, M.D., Maximilian Mossner, B.S., Susanne Ganepola, M.D., Arne Müßig, M.D., Kristina Allers, Ph.D., Thomas Schneider, M.D., Ph.D., Jörg Hofmann, Ph.D., Claudia Kücherer, M.D., Olga Blau, M.D., Igor W. Blau, M.D., Wolf K. Hofmann, M.D., and Eckhard Thiel, M.D.


Infection with the human immunodeficiency virus type 1 (HIV-1) requires the presence of a CD4 receptor and a chemokine receptor, principally chemokine receptor 5 (CCR5). Homozygosity for a 32-bp deletion in the CCR5 allele provides resistance against HIV-1 acquisition. We transplanted stem cells from a donor who was homozygous for CCR5 delta32 in a patient with acute myeloid leukemia and HIV-1 infection. The patient remained without viral rebound 20 months after transplantation and discontinuation of antiretroviral therapy. This outcome demonstrates the critical role CCR5 plays in maintaining HIV-1 infection.


Source Information

From the Department of Hematology, Oncology, and Transfusion Medicine (G.H., D.N., M.M., S.G., A.M., O.B., I.W.B., W.K.H., E.T.) and the Department of Gastroenterology, Infectious Diseases, and Rheumatology (K.A., T.S.), Campus Benjamin Franklin; and the Institute of Medical Virology, Campus Mitte (J.H.) — all at Charité Universitätsmedizin Berlin; and the Robert Koch Institute (C.K.) — all in Berlin.

Drs. Hofmann and Thiel contributed equally to this article.

Address reprint requests to Dr. Hütter at Medical Department III Hematology, Oncology, and Transfusion Medicine, Charité Campus Benjamin Franklin, Hindenburgdamm 30 D-12203 Berlin, Germany, or at gero.huetter@charite.de.

http://finance.yahoo.com/news/...ood-Announces-1-prnews-14333913.html

Cord Blood Announces $1 Million Reduction in Long Term Debt

   * Thursday February 12, 2009, 6:00 am EST

SANTA MONICA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that between January 1, 2009, and today, it has reduced its long term debt by approximately $1 million.

The Company previously said in press releases and CEO interviews that a major focus is to reduce debt and strengthen the Cord Blood America balance sheet. The mentioned debt was either converted into equity of reduced by principal cash payment. Cord Blood America said the effort to further reduce debt will continue throughout 2009.

CEO Matthew Schissler commented: "It's a start. De-levering our balance sheet coupled with strategic growth and acquisitions are the primary goals for 2009. I'm certain shareholders would agree that removing debts will help put the company in a strong position for long term growth in the stem cell industry."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

MoneyTV-Umbilical Cord Blood Stem Cell Storage
13. Februar 2009
http://www.youtube.com/watch?v=yQC_32u6hn4

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6412518

...As of February 12, 2009 a total of 942,884,111 shares of the Company's currently authorized 950,000,000 shares of Common Stock are outstanding.

http://www.reuters.com/article/domesticNews/idUSTRE51E12220090215

Obama to lift ban on stem cell research soon
Sun Feb 15, 2009 10:01am EST

WASHINGTON (Reuters) - U.S. President Barack Obama will soon issue an executive order lifting an eight-year ban embryonic stem cell research imposed by his predecessor, President George W. Bush, a senior adviser said on Sunday.

"We're going to be doing something on that soon, I think. The president is considering that right now," Obama adviser David Axelrod said on "Fox News Sunday."

In 2001, Bush limited federal funding for stem cell research only to human embryonic stem cell lines that already existed. It was a gesture to his conservative Christian supporters who regard embryonic stem cell research as destroying potential life, because the cells must be extracted from human embryos.

Embryonic stem cells are the most basic human cells which can develop into any type of cell in the body.

Scientists believe the research could eventually produce cures for a variety of diseases, including Parkinson's disease, diabetes, heart disease and spinal cord injuries.

Obama vowed to reverse Bush's ban during his presidential campaign and in his inaugural address last month promised to return science to its proper place in the United States.

The U.S. Food and Drug Administration last month cleared the way for the first trial to see if human embryonic stem cells could treat people safely.

The trial will try to use stem cells from already existing lines to regrow nerve tissue in patients with crushed spinal cords.

Stem cells are the body's master cells, giving rise to all the tissues, organs and blood. Embryonic stem cells are considered the most powerful kinds of stem cells, as they have the potential to give rise to any type of tissue.

(Reporting by Alan Elsner; Editing by Eric Beech)

© Thomson Reuters 2009 All rights reserved

http://newmexicoindependent.com/19228/...research-passes-state-senate

http://politicalticker.blogs.cnn.com/2009/02/19/...urn-stem-cell-ban/

February 19, 2009
Republicans urge Obama to overturn stem cell ban

...The Republicans said that stem cell research holds "great promise" for Americans suffering from afflictions like Parkinson's disease, spinal cord injuries and diabetes.

http://ih.advfn.com/...125706&article=36346806&symbol=NB^CBAI

...The television program can also be viewed online immediately at http://www.moneytv.net/.

http://biz.yahoo.com/prnews/090220/la73335.html?.v=1

In Analyst Interview, Cord Blood Provides Details of Special Shareholder Meeting
Friday February 20, 5:00 am ET

SANTA MONICA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company ( http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, provided details of the Company's special shareholder meeting in March.

ADVERTISEMENT
The complete interview is available at: http://www.stoxrox.com/cbai-2-18-09-e.mp3

In the interview, Mr. Schissler explains why the Company is asking for an increase in authorized shares. He explains that authorized is "vastly different from outstanding" and the Company currently has no commitments or understandings for the issuance of additional outstanding shares other than those currently on file at the SEC.

"Our goal is to be ahead of the game. We want to grow the Company into a global leader in the storage of stem cells and that includes the ability to act and react quickly. We also want to benefit from what we believe will be greatly increased research in this sector. This lets us control our destiny," Mr. Schissler said. Asked why Cord Blood America is asking for such a large increase in authorized shares, the Company's founder said "this is a time-consuming, costly process and we only want to do it once in the Company's history."

...

www.finanznachrichten.de/...s-to-be-cash-flow-positive-008.htm

25.02.2009 11:01
Cord Blood America Restructures Debt; Projects to be Cash Flow Positive

SANTA MONICA, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced an agreement with Shelter Island Opportunity Fund to restructure its current outstanding debt.

"The restructuring is a major step forward for Cord Blood America. With the signing of the agreement, Cord Blood America projects it will become cash flow positive for the first time in its history," said Matthew Schissler, Founder and CEO. "We anticipate formally being able to announce this when we file our quarterly numbers for period ending June 30, 2009."

"We have emphasized to our shareholders that reducing debt is a major focus in 2009," Mr. Schissler said. "This agreement provides us the opportunity to follow through on our commitment." The Company recently announced that since the beginning of 2009, it has reduced long term debt by more than $1 million.

...(weiter siehe LINK)

www.marketwire.com/press-release/Cord-Blood-America-957764.html

Mar 05, 2009 09:45 ET
Cord Blood America Top Stock Performer in ETF Innovators Global Stem Cell and Regenerative Medicine Index

SANTA MONICA, CA--(Marketwire - March 5, 2009) - On the day that President Obama's White House Health Care Summit commenced, Cord Blood America, Inc. (OTCBB: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, reported that the Company, now listed on the ETF Innovators Emerging Stem Cell Index of U.S.-listed stocks, is the top stock price gainer year-to-date, up 279.2 percent. For more information, see Cord Blood America's Social Media News Room and Blogs at Intelligendo.com.

The analysis is available at: www.biomedreports.com/articles/...-of-stem-cell-index-ytd.html

... (weiter siehe LINK)

www.finanznachrichten.de/...-cell-funding-restrictions-008.htm

09.03.2009 15:24
Cord Blood America Sees Significant Positives in President Obama's Lifting of Stem Cell Funding Restrictions

SANTA MONICA, Calif., March 9 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it believes the executive order signed today by President Obama eliminating restrictions on Federal funding of stem cell research is a significant move forward for the entire stem cell sector.

"Scientists are confident that stem cell research will lead to fundamental improvements in the treatment of heart disease, diabetes, Parkinson's disease and other of our most difficult to treat illnesses," said Matthew Schissler, Cord Blood America Founder and CEO.

... (weiter siehe LINK)

www.marketwatch.com/news/story/...F404-4A60-AE9C-67AE5EE93061}

Obama ends stem-cell ban, asks for science with moral values
By Rex Nutting
Last update: 12:01 p.m. EDT March 9, 2009

WASHINGTON (MarketWatch) -- President Barack Obama lifted a ban on federal funding for stem-cell research, calling on Monday for a return to integrity in the government's scientific strategy. "It is about ensuring that scientific data is never distorted or concealed to serve a political agenda - and that we make scientific decisions based on facts, not ideology," Obama said. Stem-cell research has great promise for cures and treatments in many diseases, especially of the brain and nervous system. But most stem cells have come from human embryos. Obama said he would resist any research that leads to human cloning, calling it dangerous and "profoundly wrong.

www.finanznachrichten.de/...hareholder-special-meeting-008.htm

25.03.2009 10:03
Cord Blood America Announces Results of Shareholder Special Meeting

SANTA MONICA, Calif., March 25 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that its shareholders at a Special Meeting on March 23, 2009, have overwhelming approved management's proposal to increase the number of authorized (not outstanding) common shares. The vote is being certified, at which time Cord Blood America will file the results with the U.S. Securities and Exchange Commission.

About Cord Blood America

Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI), visit our website at www.corcell.com/. For investor information, visit www.cordblood-america.com/.

CONTACT: Paul Knopick E&E Communications 949/707-5365 pknopick@eandecommunications.com

www.finanznachrichten.de/...porting-cord-blood-storage-008.htm

27.03.2009 10:01
Cord Blood America Applauds Congressional Effort Supporting Cord Blood Storage

SANTA MONICA, Calif., March 27 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it strongly supports the Family Cord Blood Banking Act introduced in the U.S. House of Representatives.

The legislation will provide tax incentives for the medical expenses for those families choosing this potentially life-saving investment. It amends the Internal Revenue Code to add cord blood banking services as a qualified medical expense. "This would allow individuals and couples to pay for umbilical cord blood banking services through health savings accounts, flexible spending accounts, medical expenses tax deduction and health reimbursement arrangements," said Matthew Schissler, CEO and Founder, Cord Blood America.

The legislation was introduced by Representatives Wally Herger (R-CA.), Rep. Ron Kind (D-WI), Mike Thompson (D-CA), Artur Davis (D-AL), and Bill Pascrell Jr. (D-NJ). The Congressmen in a press statement said "umbilical cord blood stem cells have been used in more than 14,000 transplants around the world and to treat more than 70 diseases in adults and children. The legislation could make this storage an option for more families facing potentially life-threatening diseases, increase the supply of cord blood stem cells and lower the costs for families in the future."

...(weiter siehe LINK)

www.finanznachrichten.de/...ny-commitment-to-expansion-008.htm

09.04.2009 11:01
Cord Blood America Announces First Storage Sale in Germany; Commitment to Expansion

SANTA MONICA, Calif., April 9 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said that its international partner, a.bourkas Co., United, Greece, has established a sales operation, and completed their first sale in Germany.

"Europe is starting to look more closely at the collection and storage of umbilical cord blood, which contains stem cells that could be useful for treatment of diabetes, heart disease and other illnesses that are currently impossible to cure," said Matthew Schissler, Cord Blood America Founder and CEO.

"We have been in a partnership in Greece since 2006 and we are very encouraged by their efforts to bring this life saving process to other nations on the European continent," Mr. Schissler said. "We see this as a new, potentially very profitable frontier and we are pleased to be among the leaders in this effort. We are committed to expansion and growth."

...(weiter siehe LINK)

www.finanznachrichten.de/...-817-000-in-long-term-debt-008.htm

23.04.2009 11:01
Cord Blood America Further Reduction, $817,000, in Long-Term Debt
SANTA MONICA, Calif., April 23 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, which recently announced it has decreased long-term debt by $1.75 million in 2009, said today it has eliminated another $817,000 of long-term debt.

"The remaining debt with YA Global Investments, formerly Cornell Capital Partners, has been assigned to an existing institutional investor. CBAI and YA Global Investments agreed on a one time common share settlement for liquidated damages in connection with assigning the outstanding principal and interest to the existing investor. With this assignment, CBAI has no further debt with YA Global Investments. Cord Blood America regards this as a key milestone on its path to being able to operate on its cash flow," said Matthew Schissler, Cord Blood America Founder and CEO. "We are happy to have worked with YA Global Investments and wish them future success."

"We said decreasing debt would be one of our significant items to focus on in 2009 and we are very pleased on how we are progressing," said Mr. Schissler. "Eliminating debt makes out financial balance sheet stronger and makes Cord Blood America a better investment. We are very pleased with this development."

...(weiter siehe LINK)

23.04.2009 11:01
Cord Blood Amerika weitere Reduzierung, $ 817.000, in Long-Term Debt

Santa Monica, Kalifornien, 23. April Update wird - Cord Blood Amerika, (News) Inc. (BULLETIN BOARD: CBAI), die Nabelschnurblut-Stammzellen Erhaltung Gesellschaft (www.cordblood-america. com /) auf, um die lebensrettende Potenzial von Stammzellen für Familien bundesweit und international, die vor kurzem bekannt gegeben, dass sie abgenommen hat die langfristigen Verbindlichkeiten von $ 1,75 Millionen im Jahr 2009, sagte er heute beseitigt weitere $ 817.000 an langfristigen Darlehen.

"Die restlichen Schulden mit YA Global Investments, vormals Cornell Capital Partners, wurde zu einer bestehenden institutionellen Investor. CBAI und YA Global Investments auf eine einmalige Lösung für die Aktie pauschalierten Schadensersatz in Verbindung mit der Zuordnung der ausstehenden und Interesse für die bestehenden Anleger. Mit dieser Zuordnung, CBAI keine weiteren Schulden mit YA Global Investments. Nabelschnurblut Amerika betrachtet dies als einen wichtigen Meilenstein auf dem Weg zu können auf den Cash-Flow ", sagte Matthew Schissler, Cord Blood Amerika Gründer und CEO . "Wir freuen uns, mit YA Global Investments und wünschen ihnen eine erfolgreiche Zukunft."

"Wir haben gesagt, sinkenden Schulden wäre für uns ein wesentlicher Posten auf die in den Jahren 2009 und wir sind sehr erfreut darüber, wie wir voran", sagte Herr Schissler. "Die Beseitigung der Schulden macht die finanzielle Bilanz stärker und macht Cord Blood Amerika eine bessere Investition. Wir sind sehr zufrieden mit dieser Entwicklung."

Über Nabelschnurblut Amerika

Cord Blood Amerika (BULLETIN BOARD: CBAI) ist die Muttergesellschaft der CorCell, die die Nabelschnurblut-Stammzellen für die Erhaltung werdende Eltern und ihre Kinder. Ihre Aufgabe ist es, werden die am meisten respektierte Stammzellen Erhaltung Unternehmen in der Branche. , Die durch eine sichere und nicht-invasive Verfahren, Nabelschnurblut Stammzellen bieten eine leistungsfähige und potenziell lebensrettende Ressourcen für die Behandlung einer wachsenden Zahl von Krankheiten, einschließlich Krebs, Leukämie, Blut-und Immunerkrankungen. Wenn Sie mehr über Cord Blood America, Inc. (BULLETIN BOARD: CBAI), besuchen Sie unsere Website unter www.corcell.com/. Für Anleger Informationen, besuchen Sie www.cordblood-america.com/.

Forward-Looking Statements

Einige Aussagen in dieser Pressemitteilung sind zukunftsbezogene Aussagen, die gemäß den Safe-Harbor-Bestimmungen des Private Securities Litigation Reform Act "von 1995. Wir benutzen Wörter wie "antizipieren", "glauben", "erwarten", "Zukunft", "beabsichtigen", "planen" und ähnliche Ausdrücke kennzeichnen solche vorausschauenden Aussagen. Diese Aussagen einschließlich solcher, die das Wachstum der Industrie, neue Stammzellen-Behandlungen, und die Leistung des Unternehmens, sind nur Prognosen und unterliegen bestimmten Risiken, Unsicherheiten und Annahmen. Weitere Risiken sind identifiziert und in den Unternehmen des öffentlichen Einreichungen bei der Securities and Exchange Commission. Erklärungen sind ab dem Datum dieser Pressemitteilung und sollten sich nicht darauf verlassen, von allen späteren Zeitpunkt. Das Unternehmen Die Wertentwicklung in der Vergangenheit ist nicht notwendigerweise indikativ für die zukünftige Wirtschaftsentwicklung. Die Gesellschaft nicht verpflichtet, und das Unternehmen lehnt ausdrücklich jede Verpflichtung zur Aktualisierung der zukunftsgerichteten Aussagen, um Ereignisse, Entwicklungen, Ereignisse oder Umstände nach dem Zeitpunkt der Erklärung.

www.investorcalendar.com/IC/ClientPage.asp?ID=144202&CID=

www.finanznachrichten.de/...s-own-stem-cell-laboratory-008.htm

ih.advfn.com/...;s=NB%5ECBAI&p=0&t=20&showctype=1" style="max-width:560px" />

SANTA MONICA, Calif., May 7 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has begun due diligence to either purchase or build its own secure cryogenic stem cell bank for the storage of multiple stem cell products including umbilical cord blood stem cells.

"Over the long term, having our own facility will reduce the cost for both the processing and storage of our clients' stem cells," said founder and CEO Matthew Schissler. "Additionally, it allows CBAI to pursue new sources of revenue such as the storage of adipose tissue and peripheral blood stem cells processing and storage, and research grants much quicker than under the current structure of outsourced relationships."  "We can't grow to the size and position we seek for the future without our own laboratory. This is an important strategic step to securing further industry leadership and differentiation," Mr. Schissler said.  ...(weiter siehe LINK)

www.finanznachrichten.de/...s-own-stem-cell-laboratory-008.htm

14.05.2009 11:02
Cord Blood America Receives Commitment for $2.3 Million to Fund Its Own Stem Cell Laboratory

SANTA MONICA, Calif., May 14 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has received a commitment for up to $2.3 million to acquire or build its own state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells.

"The funding is from a private, institutional investor and allows us to focus even further on our due diligence efforts that I announced last week," said Company founder and CEO Matthew Schissler. "Certain properties of the funding will be recorded as both an asset and a liability on our books." Three hundred thousand dollars of the funding has already been received by the Company to begin the lab purchase or build out, with the additional $2 million to be paid out in future installments.

"Having our own secure cryogenic stem cell bank will provide Cord Blood America with tremendous growth potential not only with our existing cord blood processing and storage business but also emerging sciences for other types of stem cells, including peripheral blood stem cell and adipose tissues," Mr. Schissler said. "We've discussed having our own lab for quite some time. Having this funding gives us the resources needed to vigorously pursue and ultimately acquire or build our own state of the art stem cell processing and storage facility."

...(weiter siehe LINK)

..........obige Nachrichten sprechen für einen Erfolg.

mal ne Order platziert, schau mer mal....

Quelle und Volltext: news.prnewswire.com/.../story/05-14-2009/0005025930&EDATE=

Denke, dass wird ein Tenbagger (meine ganz persönliche Meinung)

Cord Blood America Receives Commitment for $2.3 Million to Fund Its Own Stem Cell Laboratory

SANTA MONICA, Calif., May 14 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has received a commitment for up to $2.3 million to acquire or build its own state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells.

Cord Blood America Inc.  Cord Blood America Inc.  OTC CBAI  0.0060  *  +0.0002 (3.45%)  6.70M

Letzte KurseHandelsplatz Letzter   Veränderung Vortag letzte Stk. Tag-Stk.  Kursspanne Zeit
Nasdaq OTC BB  0,006 $   0,00%   0,006 $  90.000  46.690.804  0,0058 - 0,0066  18:58:00  
Berlin  0,005 €  ebB 0,00%   0,005 €  60.000  430.000  0,004 - 0,005  19:00:50

jetzt einfach mal liegen lassen und schauen was die nächste zeit so kommt

...mit Schwerpunkt in Sachen Forschung und Entwicklung in Sachen Nabelschnurblut-Therapie.

Meine persönliche Meinung: zuschlagen, bevor "alle Welt" dies Papier haben möchte.

Und heute Top-New, die für einen wesentlichen Anstieg des Kurses sprechen.

Quelle und Volltext: www.google.ca/finance?q=OTC%3ACBAI

Handelsplatz Letzter Veränderung Vortag letzte Stk. Tag-Stk.  Kursspanne Zeit
Berlin  0,005 €  0,00%   0,005 €  200.000  200.000  0,004 - 0,005  10:24:00  
Nasdaq OTC BB  0,0057 $  0,00%   0,0057 $  30.000  68.518.136  -   - -    02:10:05

www.cordblood-america.com/Media/

von vita 34 zu tun...

nabelschnurblutdatenbank  ist schon seit jahren im Aufbau. Allerdings gibt es auch Kritiker die anführen, dass noch ausreichend forschungsergebnisse fehlen die eine Einlagerung von Stammzellenblut rechtfertigen.

ich denke in ein paar Jahren wir dies mehr und mehr praktiziert... Vita34 meldet seit Jahren einen Anstieg von Einlagerungen an und expandiert innerhalb Europas.

Cord ist auf dem selben Weg. 

...ist Cord Blood allemal, als vita 34. Und aus meiner Sicht sehr chancenreich.

Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory

SANTA MONICA, Calif., May 15 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Company founder and CEO Matthew Schissler, in a FirstCall In audio interview with analyst Francis Gaskins, explains the thought process behind the Company owning its own stem cell laboratory.

The interview and associated web links are available at www.investorcalendar.com/IC/ClientPage.asp?ID=145109.

An analyst report compiled by Mr. Gaskins, which details Cord Blood America's effort to become cash flow positive this year, is available at gaskinsco.com/linkto-cbai.shtml

"The laboratory will allow Cord Blood America to store the cells of its clients, potentially saving a tremendous amount of money in the long run," Mr. Schissler said. "Also, it allows CBAI to sell storage services to other cryogenic tissue storage companies, and allows Cord Blood America to diversify its stem cell storage base, opening up the market greatly. This vertical integration will create a competitive advantage for the Company."

For further updated information, please follow Cord Blood America at twitter.com/StemCellBanking, twitter.com/cbai, and stem-cell-banking.blogspot.com/ .

About Cord Blood America

Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI), visit our website at www.corcell.com/. For investor information, visit www.cordblood-america.com/.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

www.finanznachrichten.de/...wning-stem-cell-laboratory-008.htm

 commitment for stem cell laboratory

research.scottrade.com/public/markets/news/...y=100-138x0112-1

0,008 $  5.000

CBAI diluted wie sau... volumen steigt kontinuierlich, käufer letztens auch...

 

hier ist super long ein guter plan.  nix für daytrader... dafür aber richtig viel drin wenn 2010 der cash flow stimmt.

nur meine Meinung

www.finanznachrichten.de/...s-and-corporate-developmen-008.htm

19.05.2009 19:53
Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments

SANTA MONICA, Calif., May 19 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it will hold a conference call on Thursday, May 21st at 11 a.m. Eastern time to discuss 2009 first quarter results for the period ended March 31, 2009. At that time, Company management will also discuss recent corporate developments and the outlook for the balance of the year.

Interested parties may access the call by dialing 877-627-6555 (domestically) or 719-325-4931 (internationally) and referencing passcode 3112433. There will also be a replay of the call available for five days at the conclusion of the call. Parties desiring to listen to the replay may dial 888-203-1112 (domestically) or 719-457-0820 (internationally) and use passcode 3112433.

SANTA MONICA, Calif., May 19 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it will hold a conference call on Thursday, May 21st at 11 a.m. Eastern time to discuss 2009 first quarter results for the period ended March 31, 2009. At that time, Company management will also discuss recent corporate developments and the outlook for the balance of the year.

Interested parties may access the call by dialing 877-627-6555 (domestically) or 719-325-4931 (internationally) and referencing passcode 3112433. There will also be a replay of the call available for five days at the conclusion of the call. Parties desiring to listen to the replay may dial 888-203-1112 (domestically) or 719-457-0820 (internationally) and use passcode 3112433.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Quelle + Volltext: news.prnewswire.com/.../story/05-19-2009/0005029354&EDATE=

Übersetzungshilfe: translate.google.de/translate_t#

+10,20 OTC BB - 0,0054

 

11 mio in buy

2,7 mio sell

Cord Blood America Inc. (CBAI.OB: 0.0054 +10.20%) shares jumped more than 10 percent after it announced a conference call to discuss its first quarter results and corporate developments. The call is scheduled for Thursday, May 21st at 11:00 a.m. Eastern Time. Many investors are bullish on this quarter’s results given the breadth of recent news announcements.

Quelle + Volltext: theotcinvestor.com/...otc-bb-and-pinksheets-market-movers-240/

Übersetzungshilfe: translate.google.de/translate_t#

0.0056
+0.0007 (14.29%)
Delayed:   3:35PM EDT    Open:  0.00    Mkt Cap:  6.26M    P/E:      -    Dividend:      -  
 High:  0.01    52Wk High:  0.03    F P/E:      -    Yield:      -  
 Low:  0.00    52Wk Low:  0.00    Beta:  -3.19    Shares:  1.12B  
 Volume:  54.63M    Avg Vol:      -    EPS:  -0.03    Inst. Own:  0%

biz.yahoo.com/e/090520/cbai.ob10-q.html

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

There is uniformity in the belief that stem cells will play a key role in fighting disease as we move forward through this century. Some scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most intractable diseases. The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells. Cord Blood America, Inc., through its wholly owned subsidiaries, CorCell Companies Inc., and Cord Partners, Inc., markets a service to preserve the umbilical cord blood in a patented process for future use exclusively by the donating family. The collection takes less than five minutes, is painless, easy and non-invasive. Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.

Quelle + Volltext: www.baystreet.ca/users/newswire/viewarticle.aspx?id=27494

Übersetzungshilfe: translate.google.de/translate_t#

www.finanznachrichten.de/...strengthened-balance-sheet-008.htm

21.05.2009 14:07
Cord Blood America, Inc. Announces 2009 First Quarter Results / Company Reports Improved Operating Results, Strengthened Balance Sheet

SANTA MONICA, Calif., May 21 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today financial highlights for its 2009 first quarter for the period ended March 31, 2009.

Some of the highlights include:


-- Improved operating results. The Company reduced its loss from operations from $0.4 million in its 2008 first quarter to $0.3 million in the 2009 first quarter.

-- Increased gross margin. The Company increased gross margin from 45.0% in the 2008 first quarter to 52.5% in the 2009 first quarter due to a more favorable mix of business, including a significantly higher percentage of revenue coming from the sale of umbilical cord blood stem cell preservation services.

-- Strengthened balance sheet. Indebtedness under the Company's convertible debentures declined from $6.8 million one year ago to $5.6 million at the end of the 2009 first quarter. Current liabilities fell from $13.6 million to $12.4 million.

-- Strong growth in billings for Company's core business. Cord's billings in the three-month period ended March 31, 2009 was $1.2 million, compared to $1.0 million in the year earlier period as reflected in the Company's deferred revenue. Deferred revenue consists of payments for enrollment in the program and processing of umbilical cord blood by customers whose samples have not yet been collected, as well as the pro-rata share of annual storage fees for customers whose samples were stored during the year.

...(weiter siehe LINK)

Berlin  0,004 €  ebB* 0,00%   0,004 €  38.397  38.397  0,003 - 0,004  11:34:32

Zahlen des Unternehmen vom 21.05.09 zeigen eine klare Verbesserung. Weiterhin wird die neue US-Regierung wahrscheinlich das "Verbot" der Stammzellenforschung  aufheben. Sie bereits angekündigt, dafür große Summen zur Verfügung zu stellen. Das hat  e n o r m e  positive Auswirkung auf die Geschäfte des Unternehmens.   Sollte dies zutreffen wird der Aktienkurs explodieren!!

Danke im Voraus

wenn nicht die Anzahl der Aktien wäre. !10 Beschäftigte und Milliarden Aktien im Markt. Das gibt sicherlich merhrere Splits i.d. Zukunft.
Die werden wir wohl niemals bei 1,x sehen. Trotzdem: 100k gebunkert und die sehe ich mir 2012 wieder an.

Decon

siehe Beitrag von "fuerza_hercuela" vom 21.05.; siehe Link "Quelle" und "Übersetzungshilfe"

Quelle:

news.prnewswire.com/.../story/05-27-2009/0005032847&EDATE=


Cord Blood America Says Debt Reduced $4.194 Million in 2009

 

SANTA MONICA, Calif., May 27 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has reduced its secured debt by a total of $4.194 million in the first five months of 2009.


"On April 6th, 2009, Cord Blood America announced it had decreased its debt by $1.75 million this year," said Matthew Schissler, Cord Blood America Founder and CEO. "Since that time, we have further reduced our secured debt by $1.627 million and have eliminated liquidated damages totaling $817,000."


"We have been very forthright with our investors. We have said there are three strong pillars needed to take CBAI to the next level. One is debt reduction, and today's announcement shows our achievement in that sector. The second is organic growth, and our deferred revenues for the first quarter were up 20 percent. The third pillar is acquisitions, and we recently announced Cord Blood America is in the process of building or buying a stem cell laboratory for increased acquisition capacity and higher gross margin," Mr. Schissler said.


"Our strategy for 2009 is in place and we stand by our ability to perform and to make all three pillars strong and sturdy. We urge our shareholders to follow our progress in these important sectors," Cord Blood America's founder said.

doch schonmal der richtige Weg, jetzt schauen wir mal wie sich diese Sache weiterentwickelt

Nasdaq OTC BBHandelsplatz   Letzter   Veränderung   Vortag   letzte Stk.   Tag-Stk.   Kursspanne   Zeit

                                  0,0049 $  +2,08% 0,0048 $ 200.000 20.472.112 0,0047 - 0,0049 21:40:34

www.investorcalendar.com/IC/ClientPage.asp?ID=145176

......legen und abwarten. Denke, da ist was zu holen. Nachdem sie jetzt das Geld für ein eigenes Labor haben.

Meine persönliche Meinung.

habe heute St. 500.00 zu 0,003 EUR gekauft;

12 - 24 Monate liegen lassen, dann staunen!

... mit unter über den Erwarteten Effekt des eigene Labors für Aktionäre und die Zukunft der Firma...

http://www.youtube.com/watch?v=J0IiAUCffSQ

Übrigens wenn sich einer die letzte Quartalsbericht Phonekonferenz angehört hat, da wurde zumindest angedacht das CBAI Expansion in Europa plant. (Primär durch Aufkauf europ. Konkurrenten)

 

 

.....habe schon einige im Depot und warte dann mal ab !

Zwar schon ein paar Tage alt dieser Artikel, aber für Investierte bzw. demnächst Investierte auf diesem Sektor doch sehr interessant. Cord Blood wir davon profitieren. Habe mir mal einige Papierchen von denen ins Depot gelegt und warte mal ab, was da passiert. Bin da sehr positiv eingestellt.

Obama fördert Stammzellenforschung in den USA
09.03.2009

Washington (AFP) — US-Präsident Barack Obama hat eine Kehrtwende in der Stammzellenforschung seines Landes vollzogen. Die Forschung an embryonalen Stammzellen werde in den USA ab sofort wieder mit staatlichen Mitteln unterstützt und vorangetrieben, sagte Obama am Montag in Washington. Der Präsident machte die Bestimmungen seines Vorgängers George W. Bush rückgängig, die den Einsatz von Staatsgeldern stark eingeschränkt hatten.

In der Stammzellenforschung sollten die USA wieder an die Weltspitze rücken, sagte Obama. "Wir eröffnen heute eine neue Front in der Wissenschaft", kündigte er an. Zwar könne er nicht garantieren, ob diese Forschungsrichtung die Hoffnungen auf Durchbrüche bei der Heilung schwerer Krankheiten erfülle. "Ich kann aber versprechen, dass wir es versuchen werden - aktiv, verantwortungsbewusst, und mit der nötigen Dringlichkeit, um verlorenen Boden gutzumachen."

Quelle + Volltext: www.google.com/hostednews/afp/article/...5c-GylVhHxzYnFq1bvM_g

vorgestern eingestiegen,
hoffe die wird sich langsam nach Norden bewegen.


MfG

www.finanznachrichten.de/...tinuing-european-expansion-008.htm

11.06.2009 11:01
Cord Blood America Continuing European Expansion

SANTA MONICA, Calif., June 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , one of the largest umbilical cord blood stem cell preservation companies (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has begun due diligence for sales operation expansion into the European Union, specifically Belgium and Italy.

Cord Blood America's international partner, a.bourkas Co., United, has had operations in Greece since 2006 and has established a sales operation in Germany.

"This is potentially a very profitable new frontier in the stem cell industry and we are pleased to be one of the leaders in this expansion and growth," said founder and CEO Matthew Schissler. "We started small in Europe, and believe now, for a number of fiscal reasons, would be a good time to look at expansion. The value of storing umbilical cord blood stem cells at birth is becoming well known worldwide."

...0.0042 +0.0006 (+16.67%)

........noch ein Grund mehr, hier etwas zu investieren und mal eine Weile abzuwarten. Meine persönliche Meinung!

CBAI: To Continue European Expansion into Belgium and Italy

Cord Blood America, Inc. (CBAI) has begun due diligence for sales operation expansion into the European Union, specifically Belgium and Italy.

Cord Blood America's international partner, a.bourkas Co., United, has had operations in Greece since 2006 and has established a sales operation in Germany.

Quelle + Volltext: www.tradingmarkets.com/.site/news/Stock%20News/2370977/

Übersetzungshilfe: translate.google.de/translate_t#

13 mio buy

3 mio sell

preis konstant bei 0,004$

www.finanznachrichten.de/...uba-with-marketing-partner-008.htm

Cord Blood America Continues International Expansion




 

 
-- Company Enters Lucrative Markets of Panama, Bermuda and Aruba with Marketing Partner --


SANTA MONICA, Calif., June 22 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, which earlier this month announced sales operation expansion into the European Union, said today it has signed an agreement with a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba. The marketing arrangement is expected to target hospitals and obstetricians/gynecologists in those areas. Cord Blood will receive revenue from the sale of cord blood processing and storage services sold to each family. Marketing of such services will commence immediately.


"We are excited to begin marketing our cord blood processing and storage services in areas where we have the first-mover advantage," said founder and CEO Matthew Schissler. "We will be the first party offering such services in Bermuda and Aruba, and the second party in Panama. Based upon the experience in North America, we believe that being first in the market will provide us with compelling advantages. We see the storage of stem cells internationally as potentially very profitable. While the size of these overall countries is relatively small, given the highly attractive demographics of their population we believe the opportunities could be lucrative. The advantages of storing stem cells at birth, and at other times in life, are becoming well known worldwide."


Panama, with a population of 3.3 million, has become an international business center in Central America, with a fast growing economy and the highest per capita consumer spending in the region. Aruba, an affluent island in the southern Caribbean, is overseen by the Netherlands, while Bermuda, a British territory in the North Atlantic, has previously had the world's highest GDP per capita.


Quelle: news.prnewswire.com/.../story/06-22-2009/0005047601&EDATE=

In a press release out on Jun 22, 2009 Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, which earlier this month announced sales operation expansion into the European Union, said today it has signed an agreement with a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba. The marketing arrangement is expected to target hospitals and obstetricians/gynecologists in those areas. Cord Blood will receive revenue from the sale of cord blood processing and storage services sold to each family. Marketing of such services will commence immediately.

Quelle: www.tradingmarkets.com/.site/news/Stock%20News/2383801/

Übersetzungshilfe: translate.google.de/translate_t#

ich hoffe, hier passiert bald mal wieder etwas positives (am Kurs) - allein so recht glauben kann ich es nicht mehr...

Technisch/taktisch mMn : Geld futsch!

....einfach einige in Depot legen und abwarten. Meine Meinung.

Cord Blood America inc. (CBAI.OB: 0.0044 0.00%) shares jumped more than 20 percent following Monday’s announcement that it was continuing to expand internationally. Specifically, the company has been expanding its sales operations in the European Union and signed a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba.

Quelle: theotcinvestor.com/...otc-bb-and-pinksheets-market-movers-304/

Übersetzungshilfe: translate.google.de/translate_t#

........für eine innovative Geldanlage mit Zukunft!

Cord Blood America Hires Management Team for Its New Stem Cell Laboratory

 

SANTA MONICA, Calif. and LAS VEGAS, July 10 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today it has hired famed Immunologist Dr. Geoffrey John O'Neill as its new Laboratory Director and Brian Pockett as Vice President of Laboratory Operations.


Cord Blood America recently announced it is opening a state-of-the-art laboratory for the storage of multiple stem cell products, including umbilical cord blood stem cells, in Las Vegas, Nevada.


"We are pleased that two such distinguished, experienced, successful professionals will be overseeing our new lab," said Company founder and CEO Matthew Schissler. "The lab will be used to process and store umbilical cord blood stem cells, to store other forms of stem cells such as peripheral blood stem cell and adipose tissues, and for research and product development."


Dr. O'Neill was Laboratory and Scientific/Medical Director for Cryo-Cell International Inc. in Florida and was Laboratory Director for the Bio-Matrix Scientific Group Inc., a San Diego biotech research and development firm in the stem cell sector. He received a Ph.D. in Immunology from the University of Glasgow, Scotland, and is the author or co-author of more than 75 publications in his field in which he has won a number of significant honors.


Mr. Pockett has more than 30 years professional experience in operations, business development, marketing, sales and financial and grant development. He has served as a consultant on global distribution, product development, commercialization, investment and intellectual properties for some of the largest companies in the U.S. He also served as Managing Director and Chief Operating Officer for Bio-Matrix Scientific Group Inc.


news.prnewswire.com/.../story/07-10-2009/0005057738&EDATE=

.........sehr innovative Firma mit internationalen Ambitionen die sich langfristig auszahlen werden!

......werde meine Stücke auch noch ein wenig aufstocken !

ANPI, Taxus FDA approval
www.streetinsider.com/FDA/...t+Liberte+Long+Stent/4799287.html

........nach oben drin für den Kurs. Äußerst innovatives Unternehmen mit internationalen Ambitionen.

PSAR Trigger...Freitags verkäufer raus ?? :-)

 

bigcharts.marketwatch.com/charts/...;rand=3865&mocktick=1" style="max-width:560px" />

Cord Blood America Highlights Significant 2009 Progress




 

 



SANTA MONICA, Calif. and LAS VEGAS, July 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today said its accomplishments in the first half of 2009 are the most significant in the Company's history and Cord Blood America is progressing to its goal of being the most important company in stem cell storage in the world.


January 6 - Launched the first social media campaign in the industry to start a public conversation about the potential usefulness of stem cells and the importance of storing umbilical cord blood stem cells.
January 9 - Established its three pillars of success for 2009: Organic growth, acquisitions and debt reduction leading to a healthy balance sheet.
February 9 - The Obama Administration announces its plan and support of stem cell research in the United States; Cord Blood America is listed on the ETF Innovators Stem Cell 40 company index.
February 12 - CBAI announces $1 million reduction in long term debt.
February 25 - CBAI announces restructuring of long term debt to free up cash flow for the company.
March 5 - CBAI noted as the top stock performer on ETF Innovators Stem Cell index, with a year-to-date stock price increase of 279 percent.
April 5 - Congress introduces legislation to promote Family Banking of Umbilical Cord Blood stem cells; CBAI announces its total long term debt reduction at $1.75 million.
April 9 - CBAI announces its first customer in Germany, noting its dedication to organic growth.
April 23 - CBAI announces additional debt reduction of $817,000.
May 7 - CBAI says it will acquire or build its own stem cell processing and storage laboratory, eliminating the need to outsource lab services and projecting a significant increase in gross profit once complete.
May 14 - CBAI announces it received a $2.3 million commitment to finance the building of its stem cell lab.
May 27 - CBAI announces debt has been reduced by $4.194 million in 2009.
June 11- CBAI announces additional expansion in Europe.
June 22 - CBAI announces contracting independent affiliate to sell services in Caribbean and Central America.



Since the end of the mid-point of 2009, Cord Blood America has further secured $7.5 million in long term equity financing for growth and acquisition opportunities; announced it has begun building the one of the largest stem cell labs in the U.S.; and announced hiring of an experienced, successful management team to manage its new laboratory


"On January 6, 2009, the closing CBAI stock price was $0.0017. On July 10, 2009, the closing stock price was 0.0033, a 94% increase in 6 months of trading. That's not where we want to be, we are still very undervalued, and I understand that the day-to-day swings of our very liquid and volatile stock price cause some investor concern," said Matthew Schissler, Chairman and CEO. "I tell investors to take a snapshot of the last six months, not six hours. Micro cap stocks are perhaps not for the faint of heart. We believe we're building a very valuable company and this snapshot of the past six months shows our progress."


"In January, CBAI stated its mission is to lay the foundation for a much stronger healthier company by the end of 2009, which included organic growth, acquisition and debt reduction. As you can see by these highlights, we remain laser-focused on executing these strategies," Mr. Schissler said. "Because of our focus, we were able to raise significant funding to build a lab with the future growth opportunities it affords us. We are also pleased by the current support of stem cell research in Washington, D.C. and Congressional and state legislative focus on family stem cell banking legislation."


About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.


Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.


Quelle: news.prnewswire.com/.../story/07-20-2009/0005062336&EDATE=

Übersetzungshilfe: translate.google.de/translate_t#

Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview




 

 


SANTA MONICA, Calif. and LAS VEGAS, July 22 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that its founder and CEO Matthew Schissler was featured on Monday in a television interview on KVVU Fox News Las Vegas, in which he discusses the 17,000 square foot facility in Las Vegas, Nevada that it recently leased to develop a state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells.


"Since we announced earlier this month that we had leased the Facility, there has been tremendous interest from parties in the Western United States in discussing opportunities to partner with the Company," said Mr. Schissler. "In addition to our current cord blood stem cell business, we are excited about having the capability to process and store multiple forms of stem cells, and expect to begin generating different revenue streams from the sale of these services in early 2010."

The entire interview is available at www.cordblood-america.com.

Quelle + Volltext: news.prnewswire.com/.../story/07-22-2009/0005064444&EDATE=

Übersetzungshilfe: translate.google.de/translate_t#

Durch den Regierungswechsel in den USA und die damit verbunde Förderung, wie z.B. der Stammzellenforschung, wird Cord Blood außergwöhnlich provitieren. Die Berichte der letzten Monate bestätigen dies. Es ist in absehbarer Zeit damit zu rechnen, dass Cord Blood enorme Gewinne einfahren wird. Der Aktienkurs wird dann explodieren.

hoffe wir haben den boden gesehen.

lg speku

.......na mal sehen !

Cord Blood - das Zukunftsunternehmen !

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.


Click here to view social media version of this release.


Click here to visit the Cord Blood America Social Media Newsroom.


Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Quelle: news.prnewswire.com/.../story/07-22-2009/0005064444&EDATE=

Übersetzungshilfe: translate.google.de/translate_t#

Cord Blood America Inc. (OTCBB: CBAI | Quote | Chart | News | PowerRating) through its subsidiaries, provides private cord blood stem cell preservation services to families in the United States. It also engages in collecting, processing, and preserving peripheral blood and adipose tissue stem cells, which allows individuals to privately preserve their stem cells for potential future use in stem cell therapy. In addition, the company engages in the collection, transportation, testing, and preservation of umbilical cord blood. Further, it creates direct response television and radio advertising campaigns, including media placement and commercial production; involves in the placement of advertising in television and radio outlets; and production of advertising content, including television commercials and radio copy. Additionally, the company engages in procuring and setting up call centers; editing, dubbing, and distribution of radio and television commercials; and procuring and placing print advertising, as well as provides advertising and marketing consulting services relating to the customer''s marketing campaign. The company is headquartered in Santa Monica, California. With 1.58 billion shares outstanding and 67,300 shares declared short as of June 2009, there is no longer a failure to deliver in shares of CBAI. According to quarterly data provided by the SEC, there were still 4,342,860 shares of CBAI that were failing-to-deliver as of September 18, 2007.

Quelle: www.tradingmarkets.com/.site/news/Stock%20News/2438494/

Übersetzungshilfe: translate.google.de/translate_t#

;-)

wär hätte da schon was gegen ?

lg speku

auf einen günen freitag

investorshub.advfn.com/boards/read_msg.aspx?message_id=39892815
www.skymarkresearch.com/cbai.pdf

news.prnewswire.com/.../story/07-30-2009/0005068745&EDATE=

Wie schätzt Ihr dieses Unternehmen ein?
Wie sind die rechtlichen Rahmenbedingungen hinsichtlich Stammzellenforschung?

ist meine Meinung

Cord Blood America Retires $2.53M Obligation
www.finanznachrichten.de/...es-dollar-2-53m-obligation-008.htm

05.08.2009 11:01

SANTA MONICA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has retired $2.53M of long-term debt.

"The two notes signed in February and March of 2007 respectively, between CBAI and the Shelter Island Opportunity Fund (SIOF), have been retired as of August 3, 2009. With this debt retirement, CBAI has only the put option agreement obligation with SIOF remaining on its balance sheet. Cord Blood America regards this as a key milestone on its path to being able to operate debt free," said Matthew Schissler, Cord Blood America Founder and CEO. "Shelter Island provided us with the capital to purchase CorCell, which is the first licensed family cord blood banking company in the United States. Using their financing allowed us to establish CBAI as one of the largest domestic stem cell storage companies. Our obligation was to pay the notes in full before the February 28, 2010 maturity date. We are happy to have met the obligation and have saved a significant amount of interest payments because of early payoff."

"We have repeatedly said that decreasing debt would be one of our significant items to focus on in 2009," said Mr. Schissler. "Eliminating debt makes our financial balance sheet stronger and makes Cord Blood America a better investment. We are very pleased with this development."

...(weiter siehe LINK)

8/7, MoneyTV with Donald Baillargeon

Date :     08/07/2009 @ 5:00AM
Source :     MarketWire
ih.advfn.com/...636179&article=38951001&symbol=NB^CBAI

LOS ANGELES, CA -- (Marketwire) -- 08/07/09 -- Bioterrorism detection, stem cell storage lab, "Dead of Night" movie and mortgage advice; this week on MoneyTV, hosted by anchor Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (www.moneytv.net), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.

Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.

The television program can also be viewed online immediately at www.moneytv.net.


Featured companies on this week's program include:

Cord Blood America, Inc. (OTCBB: CBAI) CEO Matthew Schissler talked about the company's new laboratory in Las Vegas, scheduled to go online in October.

messages.finance.yahoo.com/...mp;mid=23257&tof=1&frt=2

Meint Ihr hier geht wirklich was?
Ich bin eingestiegen und hoffe das Beste.
Über 1 Mrd. Aktien im Umlauf. R/S winkt schon oder?

Greetings

Hi,

 

ja hier geht sicher etwas. Das Unternehmen ist seit Jahren im Aufbau, Kundenzahlen steigen langsam aber stetig, Schulden werden mit Nachträglichkeit reduziert, neues Labor und kein Regierungsveto mehr wie zu Bushzeiten (Betrifft ja CBAI nicht direkt, da die nur lagern, sondern was man mit dem Cryozellen machen kann) . Wenn man sich den dt. Konkurrenten Vita 34 ansieht (aktie bei ca.  Euro) kann man ablesen, dass die Lagerung von Stammzellen, Nabelschnurblut etc. in Dtl. groß im kommen ist (und das trotz Zweifler). Da der Markt in den USA immens größer ist, Amerikanische Bürger tendentiell noch einfach manipulierbar sind und auf Trends aufspringen, denke ich wir haben es mit einer kommenden Boombtanche zu tun.  

 

Zwecks R/S: Diluttion ist schon krass bei CBAI. immer wenn ich nachkaufe werden in Berlin  666.667 Aktien (exakt 2000Euro) angeboten. Kaum ist meine Order durch sind plötzlich wieder die fehlenden Stücke auf 666.667 aufgestockt. Die Kurssprünge der Aktie kamen bis jetzt immer zustande wenn die Dilution kurz ausgesetzt wurde.

Positiv anzumerken ist das relativ hohe volumen in den USA und langsam auch in DTL.  D.h.Interesse ist da, wir müssen halt ausharren bis alle Aktien im Umlauf sind. Je nach entwicklung des Kurses wird der R/S wohl kleiner ausfallen als zb. bei Genta. Bin mit 200k drin und habe vor nach dem Urlaub auf 1Mio oder mehr aufzustocken. Diese Aktie wird einschlagen, die Frage ist nur wann.

 

Gruss

Polemarchos

Vita34 Kurs ca. 5 Euro

www.cordblood-america.com/

twitter.com/cbai

by IPOdesktop.com

Cord Blood America Inc. (CBAI.OB)
gaskinsco.com/linkto-cbai.shtml

stockcharts.com/charts/gallery.html?cbai

17.08.2009 11:02
Cord Blood America Says Balance Sheet Significantly Strengthened in 2009

www.finanznachrichten.de/...antly-strengthened-in-2009-008.htm

ih.advfn.com/...;s=NB%5ECBAI&p=0&t=20&showctype=1" style="max-width:560px" />

RBC Capital Markets - Angiotech Pharmaceuticals neues Kursziel

08:03 24.09.08
www.ariva.de/...ceuticals_neues_Kursziel_RBC_Capital_Markets_n2752144

Rating-Update:

Toronto (aktiencheck.de AG) - Die Analysten von RBC Capital Markets stufen die Aktie von Angiotech Pharmaceuticals (Profil) unverändert mit "outperform" ein. Das Kursziel werde von 4,00 auf 2,00 USD gesenkt. (24.09.2008/ac/a/u)